US Non-Invasive Prenatal Diagnostics - Market Insight

Press Release   •   Jun 19, 2013 14:29 IST

The US prenatal diagnostics market is one of the largest markets in the world for fetal monitoring, diagnostics, and predictive testing. It consists of a series of physician prescribed tests for monitoring maternal and fetal health. The current invasive technologies such as CVS and amniocentesis that are used to detect chromosomal abnormalities pose serious risks of miscarriages and are being replaced by the non-invasive prenatal diagnostics technologies.

Although NIPD is a relatively nascent segment of the prenatal diagnostics, it presents a lucrative growth potential to industry participants. The segment is mainly supported by rising incidences of fetal health-related abnormalities and the urgent need for safe, accurate and early diagnosis. Products such as MaterniT21 Plus, Verifi, and Harmony prenatal tests are the current tests available in the market. Around 100,000 samples were likely tested by MaterniT21 plus test alone by the first quarter of 2013 since its launch.

Further the report “US Non-Invasive Prenatal Diagnostics - Market Insight”, provides a transparent view on the present regulatory framework elaborating on the existing loopholes. A thorough analysis has been done illustrating the views of regulatory authorities, players and consumers towards the regulatory stringency, and the direction of regulations in the future have also been covered.

Currently, the US NIPD sector is characterized by the presence of players like Sequenom, Verinata, Ariosa and Natera. These companies are effectively taking steps to promote their LDTs among the US population especially targeting physicians to recommend their products. In future, the launch of Natera’s test is expected to impact the market significantly, thereby boosting the potential size and sample volume.

The report, which provides a prudent analysis on the current and future size of the market weighing the possible pessimistic and optimistic scenarios, is a must buy for new market entrants in the diagnostics field, planning to enter the prenatal segment.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM450.htm

Some of our Related Reports are:

- Global Insulin Delivery Devices Market Forecast to 2017
- Genetic Testing Market Outlook to 2017 (http://www.rncos.com/Report/IM492.htm)
- Analysis of Coronary Stent in US (http://www.rncos.com/Report/IM489.htm)
- US Healthcare IT Market Outlook to 2017 (http://www.rncos.com/Report/IM487.htm)
- US Personalized Cancer Genome Sequencing Market (http://www.rncos.com/Report/IM453.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm


RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.